{"id":"W2003656303","doi":"10.1016/j.bbmt.2013.01.004","title":"Salvage Second Hematopoietic Cell Transplantation in Myeloma","year":2013,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Takeda Oncology; Terumo BCT; Health Resources and Services Administration; National Institutes of Health; Swedish Orphan Biovitrum; Otsuka America; Kiadis Pharma; Therakos; Sigma-Tau Pharmaceuticals; Medical College of Wisconsin; Tarix Pharmaceuticals; StemCyte; Blue Cross and Blue Shield Association; U.S. Navy; Osiris Therapeutics; Celgene; HistoGenetics; Teva Pharmaceutical Industries; WellPoint; Merck; GlaxoSmithKline; Leukemia and Lymphoma Society; Be The Match Foundation; Ariad Pharmaceuticals; Otsuka America Pharmaceutical; Amgen; Sanofi; U.S. Department of Defense; Genentech; CellGenix; Seattle Genetics; U.S. Department of Health and Human Services; National Marrow Donor Program","keywords":"Medicine; Multiple myeloma; Transplantation; Surgery; Salvage therapy; Progression-free survival; Hematopoietic stem cell transplantation; Progressive disease; Hematopoietic cell; Retrospective cohort study; Internal medicine; Overall survival; Haematopoiesis; Chemotherapy; Stem cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002665541,0.0001733731,0.0003685415,0.0003276946,0.0002647165,0.000336411,0.0002368669,0.0002503096,0.0009302204],"category_scores_gemma":[0.0004015521,0.00006104849,0.0003752017,0.0003003067,0.0002528047,0.0001383824,0.000286768,0.0004363275,0.0002264411],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004361924,"about_ca_system_score_gemma":0.0003336606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005115987,"about_ca_topic_score_gemma":0.0007737409,"domain_scores_codex":[0.9998428,0.00004038966,0.00001041902,0.00002555627,0.00004394977,0.00003693429],"domain_scores_gemma":[0.9998067,0.00003628104,0.00006124876,0.00001876797,0.000008368148,0.00006862068],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.007426308,0.001486313,0.4345473,0.0004254036,0.0003909595,0.01406358,0.000373906,0.003864799,0.01870308,0.0009661246,0.005501204,0.5122511],"study_design_scores_gemma":[0.001288808,0.02004831,0.8486673,0.0002614959,0.0003438558,0.08550598,0.0002167154,0.006993417,0.01969002,0.001802798,0.01514009,0.00004118884],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907627,0.006659726,0.0007667568,0.0001158071,0.00003721828,0.00002484057,0.00006875952,0.00003306867,0.001531133],"genre_scores_gemma":[0.9978696,0.001191118,0.0002566273,0.0000889664,0.00006124165,0.00001319161,0.0002244046,0.000003494508,0.0002913476],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009302204,"threshold_uncertainty_score":0.003164768,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01090599533160806,"score_gpt":0.2525937452193226,"score_spread":0.2416877498877145,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}